Feprazone compared with indomethacin in the management of rheumatoid arthritis.
A double-blind cross-over trial of feprazone 450 mg daily and indomethacin 75 mg daily was carried out in fourteen patients with rheumatoid arthritis. The analgesic and anti-inflammatory activity was indistinguishable from that of indomethacin under the conditions of the trial. Seven patients expressed a preference for feprazone and four for indomethacin. Feprazone appeared to be well tolerated and free from serious side-effects. These results suggest that feprazone will be a useful drug in the management of rheumatoid arthritis.
Adult↗